Fortrea Apresenta Solução Abrangente para Aprimorar a Diversidade e Inclusão na Pesquisa Clínica

Utilizando dados do mundo real, insights de pacientes e um processo sistemático para a criação, operação e análise da eficácia dos planos de ação de diversidade em ensaios clínicos

DURHAM, N.C., May 31, 2024 (GLOBE NEWSWIRE) — A Fortrea (Nasdaq: FTRE) (a “Empresa”), uma organização líder global de pesquisa por contrato (CRO), anunciou hoje o lançamento da sua solução abrangente e integrada para a melhoria da diversidade e inclusão (D&I) dos participantes em ensaios clínicos. A solução de D&I da Fortrea foi projetada para expandir o acesso dos pacientes a participar de ensaios clínicos e atender aos requisitos da Food and Drug Administration (FDA) dos EUA, sob a Lei de Reforma Omnibus de Alimentos e Medicamentos, para aumentar a inscrição de populações sub-representadas em ensaios clínicos.

O processo abrangente da Fortrea integra cinco componentes do planejamento e execução de ações de diversidade:

  • Consultores de evidências do mundo real pesquisam conjuntos de dados relevantes do mundo real para informar o planejamento da diversidade.
  • Especialistas em regulamentação, desenvolvimento e operações clínicas elaboram o Plano de Ação de Diversidade, validam com grupos de pacientes e negociam com os reguladores.
  • As equipes operacionais acessam várias plataformas de dados, o Conselho Consultivo de Locais da Fortrea e soluções habilitadas por tecnologia para implementar o Plano de Ação de Diversidade como parte integrante da execução dos ensaios clínicos da Fortrea.
  • O monitoramento e os relatórios são habilitados pelo exclusivo Painel de Insights de Estudo de Diversidade e Inclusão da Fortrea, fornecendo dados e visualizações acionáveis para o gerenciamento contínuo do estudo.
  • Escritores técnicos de relatórios experientes compilam dados e preparam relatórios para envio regulatório, com suporte regulatório contínuo fornecido como parte da solução de D&I.

“A pesquisa clínica que reflete uma população representativa fornece uma melhor visão de como um tratamento potencial funcionará em um ambiente do mundo real”, disse John Doyle, DrPH, presidente da Fortrea Consulting. “Requisitos regulatórios recentes codificam o progresso dos últimos anos na abordagem biofarmacêutica para aumentar a inclusão de diversas populações nos seus programas de desenvolvimento. A solução da Fortrea traz uma profunda experiência em dados do mundo real para projetar planos de D&I eficazes e realistas, juntamente com mais de 30 anos de experiência em mais de 20 áreas terapêuticas na execução de testes. Também temos um compromisso firme com a D&I, não apenas nos ensaios clínicos, mas em toda a nossa empresa, à medida que buscamos nosso propósito de oferecer tratamentos que mudam a vida dos pacientes mais rapidamente.”

A solução de D&I da Fortrea incorpora uma série de ferramentas proprietárias, incluindo avaliações epidemiológicas e de viabilidade que utilizam uma combinação exclusiva de grandes conjuntos de dados. A solução também integra contribuições de grupos de pacientes para criar insights sobre a tolerância ao protocolo e os requisitos de suporte à conduta do estudo em diferentes populações de pacientes em várias áreas e geografias da terapia. Esses insights informam os planos globais e locais de recrutamento e retenção de pacientes para o alcance de populações de pacientes sub-representadas e abordagem das barreiras à participação de ensaios clínicos.

“Para a garantia da inclusão de diversas populações de pacientes em ensaios clínicos precisamos ir além de um plano, precisamos ter discernimento e agir”, disse Mark Morais, diretor de operações da Fortrea. “Devido ao nosso abrangente programa Voz do Paciente e à nossa colaboração com diversos locais de pesquisa e redes de locais, temos um profundo entendimento do que é necessário para o sucesso no alcance de populações que tradicionalmente têm sido sub-representadas nos ensaios clínicos. Na Fortrea, somos informados pelos dados do mundo real, habilitados pelas tecnologias inovadoras e impulsionados pela nossa paixão em oferecer novas terapias para todos os pacientes.”

Visite Diversidade e Inclusão em Ensaios Clínicos em Fortrea.com para mais informação.

Sobre a Fortrea

A Fortrea (Nasdaq: FTRE) é fornecedora líder global de soluções para o desenvolvimento clínico e acesso ao paciente para a indústria de ciências da vida. Fazemos parcerias com grandes e emergentes empresas biofarmacêuticas, de biotecnologia, de dispositivos médicos e de diagnóstico para impulsionar a inovação na saúde que acelera terapias que mudam a vida dos pacientes. A Fortrea fornece gerenciamento de testes clínicos de fase I-IV, farmacologia clínica, serviços de consultoria, soluções de testes com tecnologia diferenciada e serviços pós-aprovação.

As soluções da Fortrea utilizam suas três décadas de experiência abrangendo mais de 20 áreas terapêuticas, sua dedicação ao rigor científico, insights excepcionais e uma forte rede de pesquisadores. Nossa equipe talentosa e diversificada que trabalha em mais de 90 países é dimensionada para fornecer soluções focadas e ágeis para clientes de todo o mundo.

Saiba mais sobre como a Fortrea está se tornando uma força transformadora de pipeline para paciente na Fortrea.com e siga-nos no LinkedIn e X (antigo Twitter) @Fortrea.

Contatos da Fortrea:
Fortrea para Mídia: Galen Wilson – 703-298-0802, media@fortrea.com
Fortrea para Mídia: Kate Dillon – 646-818-9115, kdillon@prosek.com

GlobeNewswire Distribution ID 9146941

Fortrea lance une solution complète pour améliorer la diversité et l’inclusion dans la recherche clinique

Exploitation des données en conditions réelles, des connaissances des patients et adoption d’un processus systématique pour développer, concrétiser et mesurer l’efficacité des plans d’action en faveur de la diversité dans les essais cliniques.

DURHAM, État de Caroline du Nord, 31 mai 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq : FTRE), ci-après la « Société », une organisation de recherche contractuelle (ou ORC) leader d’envergure mondiale, annonce ce jour la sortie de sa solution complète et intégrée ciblée sur l’amélioration de la diversité et de l’inclusion des participants aux essais cliniques. La solution « Diversité et Inclusion » développée par Fortrea est conçue pour élargir l’accès des patients aux essais cliniques et répondre aux exigences de la loi fédérale Food and Drug Omnibus Reform Act édictée par l’administration américaine des denrées alimentaires et des médicaments, la Food and Drug Administration, ou « FDA » visant à renforcer le recrutement des populations sous-représentées dans les essais cliniques.

L’approche globale de Fortrea intègre cinq axes de planification et d’exécution d’actions en faveur de la diversité :

  • Recherche des ensembles de données pertinentes en conditions réelles pilotée par les conseillers en vue de contribuer à la planification de la diversité.
  • Mise au point du plan d’action en faveur de la diversité élaborée par les experts en réglementation, développement et services cliniques, validation auprès des groupes de patients et négociations avec les autorités de tutelle réglementaires.
  • Mise en accès à de multiples plateformes de données pour les équipes opérationnelles, ainsi qu’au comité consultatif de site et à des solutions technologiques pour actionner le plan d’action en faveur de la diversité, pleinement intégré à l’exécution des essais cliniques à la main de Fortrea.
  • Suivi et reporting assurés par le tableau de bord exclusif de la solution dédié aux éclairages sur les données relatives aux notions de diversité et d’inclusion des études (Diversity and Inclusion Study Insights Dashboard), fournissant des données et des graphiques exploitables dans le cadre de la gestion continue de l’étude.
  • Compilation des données effectuée par des rédacteurs techniques expérimentés veillant également à la préparation des rapports en amont des dépôts auprès des autorités réglementaires, et appui réglementaire permanent intégré à la solution.

Pour John Doyle, docteur en santé publique et Président de Fortrea Consulting, « La recherche clinique reposant sur une population représentative donne une meilleure idée des modalités de fonctionnement d’un potentiel traitement en conditions réelles. Les nouvelles exigences réglementaires traduisent les progrès réalisés ces dernières années dans l’approche biopharmaceutique visant à améliorer l’inclusion de populations diverses au sein des programmes de développement. La solution de Fortrea apporte une expertise approfondie des données en conditions réelles pour concevoir des plans ciblés sur la diversité et l’inclusion efficaces et réalistes, et plus de 30 ans d’expérience dans plus de 20 disciplines thérapeutiques en matière d’exécution d’essais. Notre engagement sans faille envers la diversité et l’inclusion dépasse les frontières des essais cliniques pour s’étendre à l’ensemble de notre entreprise, à l’heure où nous poursuivons notre objectif de mettre plus rapidement à la disposition des patients des traitements susceptibles de changer leur vie ».

La solution « Diversité et Inclusion » développée par Fortrea intègre une série d’outils exclusifs, notamment des évaluations épidémiologiques et de faisabilité qui s’appuient sur une combinaison exclusive de vastes ensembles de données. Elle intègre également des données provenant de groupes de patients pour fournir des éclairages sur la tolérance au protocole et les exigences en matière de soutien à la conduite de l’étude pour différentes populations de patients, dans plusieurs disciplines thérapeutiques et territoires. Ces éclairages permettent d’élaborer des plans de recrutement et de fidélisation des patients à l’échelle mondiale et locale, d’atteindre les populations de patients sous-représentées et d’éliminer les obstacles à la participation aux essais cliniques.

« Garantir l’inclusion de diverses populations de patients dans les essais cliniques doit s’entendre au-delà d’un plan, ce qui demande de la perspicacité et de l’action », observe Mark Morais, chef de l’exploitation de Fortrea, avant d’ajouter : « Grâce à notre programme complet Voice of Patient (la voix des patients) et à notre collaboration avec divers centres investigateurs et réseaux de centres, nous comprenons parfaitement ce qu’il faut faire pour toucher les populations habituellement sous-représentées dans les essais cliniques. Chez Fortrea, nous nous appuyons sur des données en conditions réelles issues de technologies innovantes, et nous sommes animés d’une passion axée sur la proposition de nouveaux traitements à tous les patients. »

Pour en savoir plus, veuillez consulter la page Diversité et inclusion dans les essais cliniques sur le site Fortrea.com.

À propos de Fortrea

Fortrea (Nasdaq : FTRE) figure parmi les principaux fournisseurs de solutions de développement clinique et d’accès aux soins pour les patients dans le secteur des sciences de la vie. Nous nous associons à des entreprises émergentes et établies du secteur biopharmaceutique, de la biotechnologie, des dispositifs médicaux et du diagnostic pour stimuler l’innovation dans le domaine de la santé et accélérer la mise à disposition de traitements révolutionnaires pour les patients. Nous proposons des services de gestion d’essais cliniques de phase I à IV, de pharmacologie clinique, de conseil, d’essais différenciés axés sur des technologies habilitantes, et des services post-autorisation.

Nos solutions s’appuient sur 30 ans d’expérience dans 20 disciplines thérapeutiques, une passion pour la rigueur scientifique, des connaissances exceptionnelles et un solide réseau de centres de recherche. Notre équipe talentueuse et diversifiée répartie dans plus de 90 pays est dimensionnée pour fournir des solutions ciblées et agiles à nos clients, partout dans le monde.

Pour en savoir plus sur la manière dont Fortrea est moteur d’influence du pipeline au patient, consultez le site Fortrea.com et suivez-nous sur LinkedIn et X (anciennement Twitter) @Fortrea.

Coordonnées :
Relations médias : Galen Wilson – 703-298-0802, media@fortrea.com
Relations médias : Kate Dillon – 646-818-9115, kdillon@prosek.com

GlobeNewswire Distribution ID 9146941

Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares

INSIDE INFORMATION
REGULATED INFORMATION

Nyxoah Announces Closing of Offering and Partial Exercise of
Option to Purchase Additional Shares

Mont-Saint-Guibert, Belgium – May 31, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the closing of its previously announced underwritten public offering in the United States, which included shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union, in which 5,374,755 shares of its ordinary shares were sold at an offering price of $9.25 (EUR 8.54) per share, before underwriting discounts and commissions. This resulted in total gross proceeds, before deducting underwriting discounts and commissions and other offering expenses payable by Nyxoah, of approximately $50 million (EUR 45.9 million).

In addition, Nyxoah announced today that the underwriters of the Offering have exercised their option to purchase additional shares for 300,000 shares at the public offering price of $9.25 (EUR 8.54) per share, before underwriting discounts and commissions. This exercise will bring the total gross proceeds of the Offering to approximately $52.5 million (EUR 48.5 million) before deducting underwriting discounts and commissions and estimated offering expenses. The closing of the exercise of the option to purchase 300,000 additional shares is expected to occur on June 3, 2024, subject to the satisfaction of customary closing conditions.

Nyxoah intends to use the net proceeds from the proposed offering (i) for pre-commercialization and commercialization activities in the United States; (ii) to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to the next generation of the Genio system and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (iv) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations.

Cantor Fitzgerald & Co. acted as the sole book-running manager for the offering. Degroof Petercam acted as a co-manager.

The public offering in the United States was made pursuant to an effective shelf registration statement on Form F-3 (File No. 333-268955) that was filed by Nyxoah with the U.S. Securities and Exchange Commission (the “SEC”) and became effective on January 6, 2023. Copies of the final prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022; email: [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements may be identified by words such as “expects,” “potential,” “could,” or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include express or implied statements relating to, among other things, Nyxoah’s current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies; and statements relating to the offering, including the expected closing, the anticipated proceeds from the offering and the use thereof. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Nyxoah’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation, risks relating to market conditions and the Company’s inability, or the inability of the underwriters, to satisfy the conditions for the closing of the offering. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. Other risks and uncertainties faced by Nyxoah include those identified under the heading “Risk Factors” in Nyxoah’s most recent Annual Report on Form 20-F filed with the SEC, as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Nyxoah’s views as of the date hereof, and Nyxoah does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer

[email protected]

Attachment

GlobeNewswire Distribution ID 1000963842

Xposure announces acceptance of entries for Independent Photojournalist Award


SHARJAH: The International Photography Festival, Xposure, organised by the Sharjah Government Media Bureau, announced the acceptance of entries for the Independent Photojournalist Award (IPA) for both amateur and professional photojournalists until September 30, 2024 on the Xposure web link https://awards.xposure.net.

The Independent Photojournalist Award is dedicated to honouring and supporting independent photojournalists whose images while enhancing and complementing news stories raise awareness about vital issues and concerns all over the world.

The award includes three categories – News Journalism, dedicated to those documenting breaking news as it happens, Environmental Journalism, which highlights the problems and challenges facing the future of life on the planet, and Solutions Journalism, which is dedicated o photojournalism that deals with difficult and complex issues through rapid response and suggesting appropriate effective solutions.

Xposure allows photographers wishing to participate in the
contest to submit a maximum of 12 photos in order to compete for the award.

HAlya Al Suwaidi, Director of the Sharjah Government Media Bureau, said, ‘the Independent Photojournalist Award reflects the commitment of the International Photography Festival, Xposure, to supporting photojournalism and encouraging independent photojournalists around the world for their contributions. The Award recognises their positive impact through their work in accordance with the noble ethics and professionalism of responsible journalism.’

Al Suwaidi stressed the Xposure’s keenness to support distinguished talents who shine light on facts and global realities objectively and professionally. She underlined the importance of the role of photojournalists and journalistic image in documenting and supporting news media and information, in addition to highlighting vital global developments and social and humanitarian issues to present a complete picture to the world.

Independent Photojournalism Award requires adherence to a high e
thical framework, the work is honest and impartial, and it tells the story in journalistic terms. Newspaper stories, in particular, are presented clearly through pictures rather than words.

Source: Emirates News Agency

UAE elected Vice-Chair of ITU-T Study Group 17 Regional Group for Arab Region


MARRAKESH: Dr. Mohamed Al Kuwaiti, Head of the UAE Cyber Security Council, was elected as the Vice Chairman of the ITU-T Study Group 17 Regional Group for the Arab Region (SG17RG-ARB) during the meeting held in Marrakech, Morocco, from May 27 to 29, 2024.

The election affirms the global leading role of the UAE in the enhancement and protection of the cybersecurity ecosystems.

The Group’s meeting was chaired by Eng. Al Salehi the Director General of Oman National CERT, and attended by representatives from seven Arab countries.

It was held on the sidelines of the GITEX Africa 2024, and attended by around 450 Arab and African participants from the public sector, business leaders, government officials, cybersecurity experts, researchers, and academics.

During the meeting, Dr. Al Kuwaiti shed light on UAE’s successful strategies for fortifying and safeguarding its cybersecurity infrastructure. He also highlighted the UAE’s most impactful local and international initiatives designed to bolster cooperation in cy
bersecurity on a global scale, noting the directives of the UAE’s wise leadership to strengthen cooperation among regional countries in order to protect the regional cybersecurity system.

On the sidelines of the Opening of GITEXAfrica 2024, Dr. Al-Kuwaiti highlighted the UAE’s pioneering role in cybersecurity, underscored by its fifth ranking in the global cybersecurity index. In his speech, Dr. Al-Kuwaiti emphasised that with the rise of cyber threats, digital security is crucial for sustaining development and fostering the growth of the digital economy.

He called for intensified collaborative efforts to boost citizens’ and residents’ confidence in digital government services, thereby promoting sustainable development and the prosperity of the digital economy.

Source: Emirates News Agency

UAE Ambassador visits Gulf Radio & Television Festival in Bahrain


MANAMA: Fahd Mohamed Al Amri, the UAE Ambassador to the Kingdom of Bahrain, visited the UAE Pavilion at the Gulf Radio and Television Festival, hosted by Manama.

During the visit, the UAE diplomat was briefed by Mohammed Saeed Al Shehhi, Secretary-General of UAE Media Council, on the participation of the UAE media institutions in the event, including their most prominent television and radio productions, and the key opportunities available in the UAE media sector.

Al Shehhi stressed the UAE’s commitment to supporting the progress of Arab media and strengthening cooperation and joint efforts to develop a more efficient and impactful Arab media system based on advanced strategies that keep pace with the rapid changes in the sector and contribute to driving all aspects of sustainable development.

He commended the Kingdom of Bahrain for hosting the Gulf Radio and Television Festival, highlighting the significant opportunities the event has created to strengthen cooperation and partnerships among various Gu
lf and Arab media institutions.

Highlighting the UAE Media Council’s participation in the festival, the ambassador emphasised the Council’s significant role in supporting and developing the UAE media industry in line with the vision of the wise leadership in this regard.

He lauded the significant television and radio productions presented by the UAE media institutions at the festival and extended his congratulations on the UAE’s achievements, culminating in winning 17 of the festival’s awards.

Source: Emirates News Agency

UAE bags 17 diverse awards at 16th edition of GCC Radio & Television Festival


MANAMA: The UAE media institutions participating in the 16th edition of the GCC Radio and Television Festival, which concluded yesterday in Manama, won 17 diverse awards. Additionally, three pioneers of Emirati media were honoured: Hessa Al Ossaily; Mohamed Najib; and Ahmed Saeed Al Mansouri.

The UAE participated in the festival through the UAE Media Pavilion, organised by the UAE Media Council. The pavilion highlighted the efforts of UAE media institutions in providing modern interactive content that combines creativity, authenticity, and credibility, reaching all segments of society.

The UAE Media pavilion at the 16th GCC Radio and Television Festival received a significant turnout from officials, media professionals, and the general public. Visitors were impressed by the diversity and innovation showcased by the UAE media institutions, reflecting the sector’s remarkable progress and its ability to produce creative content that enriches the local and Arab media landscape.

Sheikh Abdulla bin Mohammed bin
Butti Al Hamed, Chairman of the National Media Office (NMO) and Chairman of the UAE Media Council, expressed his pride and appreciation for this Emirati media achievement, which confirms the UAE’s leading position in the media industry at both the Gulf and Arab levels.

“The UAE’s media achievements are a testament to the foresighted vision of its leadership, coupled with meticulous planning, diligent execution, and a commitment to continuous learning. By leveraging past successes and fostering a culture of innovation, Emirati media has demonstrably positioned itself for continued excellence,” Sheikh Abdulla said.

He explained that the UAE’s media landscape is characterised by a proactive approach to success. ‘We don’t wait for opportunities to arise; we actively identify and capitalise on them. Through strategic investments in talent, fostering exceptional abilities, and attracting inspiring individuals, we cultivate a dynamic environment that fosters creativity. The success story of Emirati media is a comp
elling narrative of vision, meticulous planning, rigorous evaluation, unwavering perseverance, and a commitment to continuous adaptation and learning. However, the cornerstone of our achievements lies in the power of collaboration – through teamwork, we achieve remarkable feats.’

Sheikh Abdulla added: “This remarkable achievement by the UAE media at the GCC Radio and Television Festival reflects the leadership’s vision for a world-class media sector in the UAE.”

He commended the inspiring model presented by UAE Media in developing the media sector and providing creative and innovative content that keeps pace with global developments, stemming from an ambitious strategic vision aimed at leading the media sector and creating an enabling, developed, and attractive environment that reflects the values and principles of the UAE.

“We believe that investing in national cadres, providing a stimulating environment for creativity, and equipping them with the skills and expertise to ensure a thriving and sustainable
media industry is the foundation for media excellence. We will continue to work on developing our strategies and programmes to ensure the sustainability of this success and achieve more achievements in the future.”

He concluded by saying that UAE Media’s presence at these events facilitates the establishment of robust partnerships with leading media institutions worldwide, fostering cross-cultural understanding and the exchange of best practices in terms of content creation and production of TV and Radio programmes.

The Festival witnessed a remarkable turnout, with over 360 entries submitted by media institutions across the Gulf and Arab regions. Among these entries, 80 were dramatic works with a combined production cost of AED800 million.

Participants competed in 46 award categories spanning television and radio programmes, dramas, and digital media. Abu Dhabi Media Network secured eight awards across various categories while Dubai Media Incorporated garnered nine awards.

The Festival also honoured thr
ee luminaries from the UAE’s media landscape: Ahmed Saeed Al Mansouri for his contributions to television; veteran radio broadcaster Hessa Al Ossaily; and esteemed sports journalist Mohamed Najib. These individuals have played pivotal roles in shaping the Emirati media scene.

The Gulf Radio and Television Festival serves as a crucial platform for fostering knowledge exchange and collaboration among media institutions in the region. The 16th edition witnessed significant advancements in the judging process, adopting a sophisticated electronic system to evaluate entries, with participation from experienced judges from the Gulf and Arab countries.

Source: Emirates News Agency

UAE field hospital in Gaza continues providing medical services to patients


GAZA: The Emirati field hospital in the Gaza Strip continues to provide its medical services without interruption to Gaza’s residents amidst the dire circumstances that the Palestinian people are experiencing, especially in the city of Rafah.

Dr. Saif Al Mehrzi, an orthopaedic surgery consultant at the UAE hospital in Rafah, explained that the field hospital, which is part of Operation Chivalrous Knight 3, continues to receive the injured, particularly children, women, and those with chronic illnesses.

He noted that the medical team has carried out several operations including a metal implant removal, and an endoscopy on an inflamed wound for a patient suffering from war-caused fractures, which helped save his limbs from amputation. The patient, Dr. Al Mehrzi explained, had been suffering from complications since undergoing surgery last October.

He affirmed that surgeries are being conducted daily to alleviate the suffering of the Palestinian people.

Source: Emirates News Agency